News and Announcements
Globacap Limited: The London start up that has issued the world’s first blockchain equity-security tokens
- Published September 26, 2018 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
KEY TAKEAWAYS:
- Globacap has created the world’s first blockchain equity-security tokens.
- These new tokens are a milestone for the security industry by allowing companies to access a larger pool of global capital.
- CEO Myles Milston says Globacap have created a platform that will change the way the world amasses capital.
Globacap has created the world’s first blockchain equity-security tokens alongside the UK Financial Conduct Authority.
The London based start up said these blockchain tokens form a legal shareholding under UK company and securities law.
These new tokens are a milestone for the security industry by allowing companies to access a larger pool of global capital.
The tokens built-in technology and processes help further transactions by fulfilling the administrative and legal requirements . These transactions are recorded on the tokens blockchain.
Globacap CEO, Myles Milston, said that the company has created a platform that will change the way the world amasses capital.
The companies mission is: “To simplify, streamline and widen access to global capital”
About Globacap Limited
The Globacap platform tokenizes illiquid assets, such as private equity, property and loans. Using blockchain technology, we help institutions with end-to-end capital raising, custody and administration services.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
